JPRN-UMIN000013467
Completed
Phase 2
Phase 2 study to evaluate the efficacy and the safety of clarithromycin, lenalidomide and dexamethasone (Personalized BiRd) for patients with relapsed or refractory multiple myeloma - Personalized BiRd for relapsed or refractory multiple myeloma
Yokohama Municipal Citizen's Hospital0 sites12 target enrollmentMarch 20, 2014
Conditionsmultiple myeloma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- multiple myeloma
- Sponsor
- Yokohama Municipal Citizen's Hospital
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Patients who have peripheral neuropathy or peripheral neuropathic pain of grade 2 or more. (2\)Patients who have had a complication of active double cancer within the past 5 years. (3\)HBs antigen positive,HCV antibody positive, HIV antibody positive patients (4\) serious mental disorders such as schizophrenia (5\) Patients with a clinical picture of pneumonia (interstitial pneumonia) or fibroid lung or an abnormal bilateral interstitial abnormality on chest CT scan regardless of the presence or absence of symptoms (6\) Patients with severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection (7\)Patients with plasma cell leukemia, cardiac amyloidosis and POEMS syndrome (8\)Ptients with thrombosis (9\)Women who are or may be pregnant (10\)Other patients who are,in the opinion of the caring investigator, unfit for enrollment in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Phase II study to investigate the efficacy and safety of ZK 219477 as first-line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC)Extensive disease (ED) stage small cell lung cancer (SCLC)EUCTR2005-000597-53-DESchering AG
Active, not recruiting
Not Applicable
Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC)on small cell lung cancer (NSCLC) stage IIIB or stage IVEUCTR2005-000586-19-DEBayer Schering Pharma AG
Active, not recruiting
Phase 1
A phase II study investigating the efficacy and safety of Vvax001, a therapeutic cancer vaccine, in patients with premalignant cervical lesions.EUCTR2019-004050-29-NLniversity Medical Center Groningen18
Recruiting
Phase 2
A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia.NL-OMON55191niversitair Medisch Centrum Groningen18
Terminated
Phase 2
A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Study to Evaluate The Efficacy and Safety of T89, drug name: Dantonic 'Registered trade mark' in Patients with Chronic Stable Angina PectorisChronic Stable Angina PectorisAnginaCardiovascular - Coronary heart diseaseACTRN12609000044224CNS Pty Ltd70